BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10831286)

  • 1. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.
    Vadhan-Raj S
    Semin Hematol; 2000 Apr; 37(2 Suppl 4):28-34. PubMed ID: 10831286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thrombopoietin in myelosuppressive chemotherapy.
    Vadhan-Raj S
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):35-8. PubMed ID: 11497230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
    Vadhan-Raj S; Verschraegen CF; Bueso-Ramos C; Broxmeyer HE; Kudelkà AP; Freedman RS; Edwards CL; Gershenson D; Jones D; Ashby M; Kavanagh JJ
    Ann Intern Med; 2000 Mar; 132(5):364-8. PubMed ID: 10691586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
    Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
    J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
    Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
    Consensus Committee of Chemotherapy Induced Thrombocytopenia, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):714-720. PubMed ID: 30293399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Apr; 13 Suppl 1():S14-8. PubMed ID: 10232362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thrombopoietin: clinical experience and in vivo biology.
    Vadhan-Raj S
    Semin Hematol; 1998 Jul; 35(3):261-8. PubMed ID: 9685172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia.
    Akahori H; Shibuya K; Obuchi M; Nishizawa Y; Tsuji A; Kabaya K; Kusaka M; Ohashi H; Tsumura H; Kato T; Miyazaki H
    Br J Haematol; 1996 Sep; 94(4):722-8. PubMed ID: 8826901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
    Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis.
    Neumann TA; Foote M
    Cytokines Cell Mol Ther; 2000 Mar; 6(1):47-56. PubMed ID: 10976539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
    Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
    Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.